Table 1.
Baseline clinical characteristics of the study patients
| Non-COPD (n=105) (n, %) | COPD (n=92) (n, %) | p-value | |
|---|---|---|---|
| Sex | |||
| Male | 70 (66.7) | 79 (85.9) | 0.002 |
| Age (years) | 64.7±10.4 | 69.5±9.4 | 0.001 |
| Stage | 0.235 | ||
| IIIB | 21 (20.0) | 25 (27.2) | |
| IV | 84 (80.0) | 67 (72.8) | |
| BMI (kg/m2) | 22.9±3.6 | 23.1±3.2 | 0.747 |
| Smoking | 0.009 | ||
| Never-smoker | 37 (35.2) | 17 (18.5) | |
| Ever-smoker | 68 (64.8) | 75 (81.5) | |
| ECOG | 0.515 | ||
| 0–1 | 85 (81.0) | 71 (77.2) | |
| 2–3 | 20 (19.0) | 21 (22.8) | |
| Pathology | 0.001 | ||
| Squamous | 24 (22.9) | 46 (50.0) | |
| Non-squamous | 81 (77.1) | 46 (50.0) | |
| FEV1 (L) | 2.18±0.91 | 1.76±0.61 | <0.001 |
| FEV1 (% predicted) | 87.93±21.70 | 71.55±21.97 | <0.001 |
| FVC (L) | 2.78±0.91 | 3.08±1.04 | 0.118 |
| FVC (% predicted) | 82.10±20.54 | 86.84±21.82 | 0.029 |
| FEV1/FVC (% predicted) | 77.39±6.11 | 57.65±9.19 | <0.001 |
| DLCO (abs) | 16.43±15.87 | 16.65±16.22 | 0.926 |
| DLCO (%) | 76.19±20.99 | 73.38±20.89 | 0.400 |
Abbreviations: Abs, absolute; BMI, body mass index; COPD, chronic obstructive pulmonary disease; DLCO, diffusing capacity of the lung for carbon monoxide; ECOG, Eastern Cooperative Oncology Group; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.